← Back to patent-cliff list
CAS 946062-02-8
(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (tert-butoxycarbonyl)glycinate
Codes: FIRT-004
Application context (from source-drug indications)
Colorectal cancerFirtecan pegolBreast cancerFirtecan pegolSolid tumourFirtecan pegolMetastatic breast cancerFirtecan pegolLymphomaFirtecan pegol
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Firtecan pegol | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(S)-4,11-diethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione→(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-4-hydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione→2-((tert-butoxycarbonyl)amino)acetic acid→(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (tert-butoxycarbonyl)glycinate→(S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl glycinate hydrochloride→tert-butyl 2-bromoacetate→7,7'-(oxybis(methylene))bis(3,6,9,12-tetraoxatetradecanedioic acid)→tetrakis((S)-9-((tert-butyldiphenylsilyl)oxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl) 10,10'-(oxybis(methylene))bis(4,17-dioxo-6,9,12,15-tetraoxa-3,18-diazaicosanedioate)→2,2',2'',2'''-((oxybis(propane-3,1,2-triyl))tetrakis(oxy))tetrakis(ethan-1-ol)→tetra-tert-butyl 7,7'-(oxybis(methylene))bis(3,6,9,12-tetraoxatetradecanedioate)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.